Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell ...